MK-2206 2HCl

目录号:S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂,在无细胞试验中IC50分别为8 nM/12 nM/65 nM;对250种其他蛋白激酶没有抑制活性。Phase 2。

规格 价格 库存 购买数量  
RMB 1789.01 现货
RMB 895.01 现货
RMB 1403.57 现货
RMB 3032.85 现货
RMB 4655.02 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献183篇:

客户使用该产品的21个实验数据:

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

  • (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

产品安全说明书

Akt抑制剂选择性比较

生物活性

产品描述 MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂,在无细胞试验中IC50分别为8 nM/12 nM/65 nM;对250种其他蛋白激酶没有抑制活性。Phase 2。
特性 MK-2206是第一个进入临床研究阶段的Akt小分子变构抑制剂。
靶点
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
体外研究

MK-2206是变构抑制剂,由pleckstrin同源结构域激活。MK-2206抑制Akt的苏氨酸308位点和丝氨酸473位点的自身磷酸化作用。另外,MK-2206阻止Akt调节的下游信号分子(包括TSC2, PRAS40,及核糖体S6蛋白)的磷酸化作用。与抑制Ras 突变型细胞系(如NCI-H358, NCI-H23, NCI-H1299, 和Calu-6)相比,MK-2206 更有效地抑制Ras野生型细胞系(如A431, HCC827, 和NCI-H292)。MK-2206和细胞毒素药剂如erlotinib 和lapatinib联用作用于肺部NCI-H460肿瘤细胞或者卵巢A2780肿瘤细胞,MK-2206也显示出协同效应。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MnXqR5l1d3SxeHnjJGF{e2G7 M3mzc|Mh|ryP M33XdVczKGh? MXXEUXNQ NXP5NFJ5UW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= M2\1NlIxPTdzME[5
A431 NEjpO2VMcW6jc3WgRZN{[Xl? NIrvPJo2KM7:TR?= NEfte3E2KGh? NGm5cIlFVVOR NF7QN2NUfXCycnXzd4V{KHSqZTDzbYdv[Wyrbnegc4YhSWu2IHHu[EBGemt? MlX3NlA2PzFyNkm=
HepG2 M2PtTGN6fG:2b4jpZ{BCe3OjeR?= MXexNEDPxE1? NVfufIF[OjRiaB?= NUDlXmI2TE2VTx?= NF7GRo9U\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI> NX7Sb2dFOjF{MEW5NlU>
Sk-Hep1 NULOW|NoS3m2b4TvfIlkKEG|c3H5 MlXCNVAh|ryP MmjvNlQhcA>? NVfEWm9bTE2VTx?= M1XTOXNmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=> NEnpV5IzOTJyNUmyOS=>
OCUT1 cells harbored PIK3CA (H1047R+/+) MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH1SpdUOyEQvF2= MWe1JIQ> MlLqSG1UVw>? MX3JR|UxRTBwMUSg{txO MV6yNVI5QTJ4Nx?=
K1 cells harbored PIK3CA (E542K+/+) NGracIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH6ZmQ6OyEQvF2= MkHjOUBl MnPRSG1UVw>? NITiSnRKSzVyPUCuOVIh|ryP NHjtUoYzOTJ6OUK2Oy=>
FTC133 cells harbored PTEN (allele deletion and R130+) MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\zN{DPxE1? MXq1JIQ> MYfEUXNQ NF[1U3VKSzVyPUCuNVgh|ryP M4LGNVIyOjh7Mk[3
C643 cells harbored HRAS (G13R+/−) NYnEeoxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\LUoRQOyEQvF2= MWW1JIQ> NIrCOIlFVVOR NWnKbmdsUUN3ME2wMlI4KM7:TR?= MUOyNVI5QTJ4Nx?=
Hth7 cells harbored NRAS (Q61R+/−) Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\zd|Y{KM7:TR?= MYG1JIQ> NV;TZnJCTE2VTx?= MYXJR|UxRTRwNTFOwG0> NGS0THkzOTJ6OUK2Oy=>
TPC1 cells harbored RET/PTC1 rearrangement M1qyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjzNHk{KM7:TR?= NIHLSJI2KGR? MkfxSG1UVw>? M3nKVmlEPTB;MD61PUDPxE1? NH;NdWkzOTJ6OUK2Oy=>
Hth74 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr4TGg{KM7:TR?= NXLNboFQPSCm NYXJcWNOTE2VTx?= MUTJR|UxRTJwMUmg{txO NFfae5YzOTJ6OUK2Oy=>
KAT18 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjENm5pOyEQvF2= MlnTOUBl NHW1O4tFVVOR M3\mWmlEPTB;ND62NkDPxE1? MnvRNlEzQDl{Nke=
SW1736 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7OXJYyODBizszN NULjRm96PSCm NUHucpFLTE2VTx?= NYTOVXp6UUN3ME20O{42PiEQvF2= MkXaNlEzQDl{Nke=
WRO M{LyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2xNFAxKM7:TR?= M{XqS|Uh\A>? MlP4SG1UVw>? NX7jeWFzUUN3ME6xNFAxKM7:TR?= NE\TdIczOTJ6OUK2Oy=>
TAD2 M321dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKxNFAxKM7:TR?= M{DCR|Uh\A>? MXrEUXNQ MoiwTWM2OD5zMECwJO69VQ>? NH:4XpEzOTJ6OUK2Oy=>
LN229 M3v5dWFxd3C2b4Ppd{BCe3OjeR?= NIPmc4oxNjVizszN M2fx[FYxKGh? NUX6PFRxTE2VTx?= NXLufZB2SXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= NXjXTGl2OjJyNUe5NVQ>
T98G NXn6fJR5SXCxcITvd4l{KEG|c3H5 M13Yd|AvPSEQvF2= M4LwWFYxKGh? MXPEUXNQ NHPoTlhCfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= MmnsNlIxPTd7MUS=
HC11 M{fKUWZ2dmO2aX;uJGF{e2G7 NYf2U4FMOTBizszN M3K4TVI1KGh? NIjDN2lFVVOR M{K4SGlvcGmkaYTzJO6zNWOjc3XpckBidmRiQVTSVEB{gW62aHXzbZM> M1TEPVIzPDJ4NkKx
MOLT-4 NEKwPYVEgXSxdH;4bYMhSXO|YYm= MojkNVAh|ryP M{PUXVQ5KGh? NYjKfoc6TE2VTx?= MnnOTWM2OD1zLkhihKnPxE1? NXy0[VJqOjJ4MUSyOFM>
CEM-R NYPQN|BRS3m2b4TvfIlkKEG|c3H5 M{G5cVExKM7:TR?= NWXRVmZXPDhiaB?= MV7EUXNQ NHjnRoZKSzVyPUOuN-KBkc7:TR?= NF;HVFQzOjZzNEK0Ny=>
CEM-S NX3tNJRGS3m2b4TvfIlkKEG|c3H5 NFqwSJcyOCEQvF2= M3rhNlQ5KGh? NXz0W5FMTE2VTx?= Mn\pTWM2OD13LkJihKnPxE1? MoH2NlI3OTR{NEO=
MOLT-4 M2\6ZmZ2dmO2aX;uJGF{e2G7 MmraNVAh|ryP MnuxNlQhcA>? M1rrPGROW09? Mn;URoxw[2u|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\SCxZjD0bIUh[2WubDDjfYNt\Q>? MXSyNlYyPDJ2Mx?=
MOLT-4 MWHGeY5kfGmxbjDBd5NigQ>? NI\EfWw16oDLzszN Mn\KOEBp Mnv3SG1UVw>? MWLJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFM1GvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> NVy5XYhQOjJ4MUSyOFM>
CEM-R MWDGeY5kfGmxbjDBd5NigQ>? NHHR[VA16oDLzszN NITDWo81KGh? MlS5SG1UVw>? MYfJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNFGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> NIT5eoEzOjZzNEK0Ny=>
CEM-S NFvuPVJHfW6ldHnvckBCe3OjeR?= MWO05qCK|ryP Mmi5OEBp MV\EUXNQ M1nCUWlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO1RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? M13DSVIzPjF2MkSz
HepG2 cell NEf2WlhMcW6jc3WgRZN{[Xl? M33sclIxKM7:TR?= NUeyb2FZOjRiaB?= NUTFZZNOTE2VTx?= MUPEc5dvemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gRWtV NFTxe4EzOzd7N{OxPS=>
HepG2 cell MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzPTGlrOzBizszN M3;3cVI1KGh? NH7xd5lFVVOR M3m4R2lvcGmkaYTzJINmdGxiZ4Lve5Rp Mnn1NlM4QTd|MUm=
HepG2 cell MnnTRZBweHSxc3nzJGF{e2G7 NX7CPGtROjBizszN MUeyOEBp NVviZ4ZkTE2VTx?= M2mxXGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVGyN|c6PzNzOR?=
GEO M2[0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjPTnBEPTByIH7N NGjLd5g4OiCq M1uxTGROW09? M2jRNGlvcGmkaYTzJINmdGxiZ4Lve5Rp NYfKS4lLOjR3OEGyN|E>
CNE-1 M4r2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWxNEDPxE1? MYi5OkBp NETm[Y1FVVOR MYLJR|UxRTJwOU[g{txO NVXHXY1EOjV|M{[5NlU>
CNE-2 NUjRRmRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLrNVAh|ryP NVrvTphrQTZiaB?= Mk\6SG1UVw>? MkXTTWM2OD12LkWzJO69VQ>? MkHwNlU{OzZ7MkW=
HONE-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCxNEDPxE1? M2HsZVk3KGh? M2n5XmROW09? MkHtTWM2OD1|LkO3JO69VQ>? MUiyOVM{Pjl{NR?=
SUNE-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxNEDPxE1? MWi5OkBp Ml7LSG1UVw>? NETC[4hKSzVyPUCuOVIh|ryP MUeyOVM{Pjl{NR?=
CNE-2 NHHxOW1HfW6ldHnvckBCe3OjeR?= NIixS5gyOCEQvF2= M4LhOFQ5KGh? MkjPSG1UVw>? M3S5VGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? Mlq5NlU{OzZ7MkW=
HONE-1 NYnmNIpqTnWwY4Tpc44hSXO|YYm= NVjqSYw6OTBizszN NFfrOI41QCCq NGThb2hFVVOR MmfaTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>? NXvOWoRqOjV|M{[5NlU>
NEC8 NXHmfVJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7tb2Z5UUN3ME2wMlA6PjVzIN88US=> MljuV2FPT0WU
P12-ICHIKAWA NVLWO3BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrxTWM2OD1yLkGxOlIh|ryP MlHyV2FPT0WU
MDA-MB-175-VII MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT3TWM2OD1yLkGzO|M5KM7:TR?= MnryV2FPT0WU
AsPC-1 NUH2RoJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\PdJp1UUN3ME2wMlIzOTJ{IN88US=> MV;TRW5ITVJ?
T47D NWTBNmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvZXWNKSzVyPUCuNlgzPSEQvF2= NHrKOnlUSU6JRWK=
HH NUn3PGNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj0R5hKSzVyPUCuN|AzQDNizszN NUG1UZU4W0GQR1XS
MOLT-16 NGr6VWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwM{CzNkDPxE1? MlrrV2FPT0WU
ES5 NE\NSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\ZU|lKSzVyPUCuN|Q1PTVizszN M1zhNnNCVkeHUh?=
RS4-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPjTWM2OD1yLkO0OlEh|ryP M{iwcHNCVkeHUh?=
KARPAS-45 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi1[JU4UUN3ME2wMlM4OzJzIN88US=> M4TvbHNCVkeHUh?=
NCI-H720 M1Tvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwM{e2O|kh|ryP M3X1W3NCVkeHUh?=
H9 M{DQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDPemVvUUN3ME2wMlM5QDh|IN88US=> NETRWGpUSU6JRWK=
EFM-19 NFrqdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq3dYJuUUN3ME2wMlQ1ODFizszN NFf2b2JUSU6JRWK=
SBC-1 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXCVGpKSzVyPUCuOFQxOzVizszN M{jMUXNCVkeHUh?=
A4-Fuk Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNE[4Olgh|ryP MYDTRW5ITVJ?
NCI-H1563 NU[wXXY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjVTWM2OD1yLkS4NVg6KM7:TR?= Mn;XV2FPT0WU
HCC1419 NVXqfZI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHLTWM2OD1yLkS4PFkzKM7:TR?= NFfNVotUSU6JRWK=
H-EMC-SS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XPTWlEPTB;MD60PVk{QSEQvF2= M4r4OnNCVkeHUh?=
BHT-101 NIXiTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfIR2JGUUN3ME2wMlUzQTZzIN88US=> MWjTRW5ITVJ?
IGROV-1 NWXpbmNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlywTWM2OD1yLkW1NlQ6KM7:TR?= MljpV2FPT0WU
HGC-27 NYKyNIRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELpdINKSzVyPUCuOVY4QDNizszN NFLnOpdUSU6JRWK=
MDA-MB-361 NIOwNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPSbHhKSzVyPUCuOVc4PjFizszN MoHHV2FPT0WU
KE-37 NHnRcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XHSGlEPTB;MD61PFI3KM7:TR?= MnLOV2FPT0WU
HCC70 NWjheXF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\oTWM2OD1yLkW5PFI4KM7:TR?= M2K4SnNCVkeHUh?=
LNCaP-Clone-FGC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS4TWM2OD1yLk[xNFQ5KM7:TR?= MYrTRW5ITVJ?
HAL-01 MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;XN2lEPTB;MD62NlE{KM7:TR?= MmrkV2FPT0WU
HT Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37kVGlEPTB;MD62N|I{QSEQvF2= NVflT3d[W0GQR1XS
MDA-MB-415 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLITWM2OD1yLk[zOlI3KM7:TR?= MkPPV2FPT0WU
NOS-1 M{fFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwNkO3NlMh|ryP MoTrV2FPT0WU
DU-145 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rlb2lEPTB;MD62OFc1PSEQvF2= MlPGV2FPT0WU
OCUB-M NWn5SmFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPDTWM2OD1yLkewPVY3KM7:TR?= MVXTRW5ITVJ?
VA-ES-BJ M1zwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXGTWM2OD1yLkezNFI2KM7:TR?= NHXqXGJUSU6JRWK=
J-RT3-T3-5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwN{S0NFMh|ryP NV7ybYF{W0GQR1XS
MOLT-4 NIrV[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTIT2tWUUN3ME2wMlgxPTh{IN88US=> NXvleo1NW0GQR1XS
NB7 NVnwVGZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvMTWM2OD1yLkiyOFEyKM7:TR?= MmLTV2FPT0WU
L-363 NXHa[2pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P2W2lEPTB;MD64N|Q1OiEQvF2= MnjxV2FPT0WU
NKM-1 M2n1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nYUmlEPTB;MD64OlI2OyEQvF2= NUDwTpVRW0GQR1XS
HOP-92 MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorwTWM2OD1yLki3NlI{KM7:TR?= NHvYTpNUSU6JRWK=
OAW-42 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwOEi3NkDPxE1? NUHDUmYzW0GQR1XS
HuO9 M1vKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Xod2lEPTB;MD65Nlc2OSEQvF2= NUPYZoQ3W0GQR1XS
MFE-280 NGHaPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwOU[0OlUh|ryP NG\DTIdUSU6JRWK=
EM-2 M1LDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj6WIxKSzVyPUCuPVc6OzlizszN NH3hRpBUSU6JRWK=
NCI-H520 NEC2cpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Tpc2lEPTB;MD65PFU6OiEQvF2= MX;TRW5ITVJ?
LB2241-RCC MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLkTWM2OD1yLkm5O|M1KM7:TR?= NEPrd4FUSU6JRWK=
SK-NEP-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\lT4lDUUN3ME2xMlE1PDh3IN88US=> MmT3V2FPT0WU
LXF-289 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG5UoVKSzVyPUGuNVcyPTZizszN MYnTRW5ITVJ?
EPLC-272H M17pUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TrVWlEPTB;MT6xO|I2PiEQvF2= NUW0N5d6W0GQR1XS
COLO-684 NFe2[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:yU3J6UUN3ME2xMlI{PzJ3IN88US=> M1;NW3NCVkeHUh?=
ES1 M3HzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXVTWM2OD1zLkK0NFY2KM7:TR?= NFLZZoRUSU6JRWK=
DOHH-2 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rtO2lEPTB;MT6yPFIxOyEQvF2= MVrTRW5ITVJ?
CTB-1 NIeyZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\KfIdKSzVyPUGuNlg6QSEQvF2= NECwWI1USU6JRWK=
G-401 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFwMkm3PVUh|ryP M1XqOXNCVkeHUh?=
LoVo NWLkVXJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTLTWM2OD1zLkOyOVM1KM7:TR?= NVfn[lRRW0GQR1XS
Ramos-2G6-4C10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn0RVVsUUN3ME2xMlM{PzBzIN88US=> MVrTRW5ITVJ?
MFM-223 NHnrbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X5VGlEPTB;MT6zOFQ3OSEQvF2= M1vzSXNCVkeHUh?=
PA-1 NVX2e49iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jLZWlEPTB;MT6zOVI3PSEQvF2= Ml:4V2FPT0WU
697 MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT2VHRKSzVyPUGuN|c3OTZizszN M2PDVXNCVkeHUh?=
QIMR-WIL M4rEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\XNGlEPTB;MT60PVEyPiEQvF2= MUPTRW5ITVJ?
HOS MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LUOmlEPTB;MT60PVU2QCEQvF2= MkPrV2FPT0WU
DMS-273 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXUTWM2OD1zLkWxPVU6KM7:TR?= MkfGV2FPT0WU
ME-180 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwNU[4PVEh|ryP M1L3U3NCVkeHUh?=
HCC2218 M{TycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;BdmlEPTB;MT62PFIzPSEQvF2= MV\TRW5ITVJ?
CAL-54 NF7Mb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFwN{GyOFIh|ryP NXPYV|Z2W0GQR1XS
OMC-1 M1vVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\yXVBmUUN3ME2xMlc1Pjd5IN88US=> NY\DdHFZW0GQR1XS
COR-L105 NXLZSIloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nTdmlEPTB;MT63PVc{PyEQvF2= NF\vSHpUSU6JRWK=
BV-173 NG\sRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPCR4dKSzVyPUGuPFExPzRizszN MYXTRW5ITVJ?
RKO MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3Uc5RKSzVyPUGuPFcyODFizszN NX[yUHpwW0GQR1XS
SNU-387 M4Wz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;yNHZKSzVyPUGuPFg1ODZizszN NUPJVHZQW0GQR1XS
SW1088 Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwOUS2NFYh|ryP NHHFSlhUSU6JRWK=
Hs-578-T NYfEZnZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTETWM2OD1{LkGxOFM{KM7:TR?= MnW4V2FPT0WU
OC-314 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTpb5ZEUUN3ME2yMlE2ODh4IN88US=> Mn34V2FPT0WU
RMG-I NH3sWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXjeHJKSzVyPUKuNVY{QThizszN MUfTRW5ITVJ?
NCI-H1395 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJwMUiwPVEh|ryP MUfTRW5ITVJ?
GAMG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvSTGtxUUN3ME2yMlI{QDR3IN88US=> MoqxV2FPT0WU
LB1047-RCC M3L4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qxdGlEPTB;Mj6yOFMyPyEQvF2= MUjTRW5ITVJ?
MN-60 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PXUWlEPTB;Mj6yPVkzOyEQvF2= NVTmO25pW0GQR1XS
OAW-28 NYO0RW9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LpUGlEPTB;Mj6yPVk2OSEQvF2= MnTHV2FPT0WU
NCI-H2228 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjSc2pKSzVyPUKuN|E2PTJizszN NWjT[2xEW0GQR1XS
ABC-1 NVrXeFVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITkNo1KSzVyPUKuN|MzPTNizszN NXLG[WNPW0GQR1XS
LS-513 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fZV2lEPTB;Mj6zN|Q5PCEQvF2= M1jMV3NCVkeHUh?=
KS-1 NVXVdlZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;RTWM2OD1{LkO4NVkyKM7:TR?= MkXTV2FPT0WU
NB69 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJwM{i5PFMh|ryP NUjpXY1sW0GQR1XS
VM-CUB-1 NFzIepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DTNWlEPTB;Mj6zPVA5OyEQvF2= MnnHV2FPT0WU
D-423MG MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLT[4xKSzVyPUKuOFExPDRizszN NYPnbJR1W0GQR1XS
EW-18 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS0TWM2OD1{LkSxPVM6KM7:TR?= NUjFb21LW0GQR1XS
YH-13 NHz3NWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnafIFRUUN3ME2yMlQ3OTV|IN88US=> MoLBV2FPT0WU
T-24 NE\me3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P2UmlEPTB;Mj60O|g5OSEQvF2= M4TMOXNCVkeHUh?=
ES8 NF;6OpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LYfmlEPTB;Mj60PVI5PyEQvF2= MUnTRW5ITVJ?
ES3 MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHD[5h3UUN3ME2yMlQ6PzV7IN88US=> MV;TRW5ITVJ?
RXF393 NEXXZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPJTWM2OD1{Lk[wOFg4KM7:TR?= NWnrfYlvW0GQR1XS
RPMI-8226 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjDOFlQUUN3ME2yMlYzQTV|IN88US=> MV\TRW5ITVJ?
AGS Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLxSYV6UUN3ME2yMlczOTN5IN88US=> NXTENol{W0GQR1XS
HCC1395 NFvSVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJwN{WxPFch|ryP MVLTRW5ITVJ?
MV-4-11 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rmVmlEPTB;Mj63OVI3PiEQvF2= NV:y[JhXW0GQR1XS
A204 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJwOEO4O|Ih|ryP Mn;yV2FPT0WU
MCF7 M3LpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXre49kUUN3ME2yMlg3OTF5IN88US=> NUPETpJOW0GQR1XS
SNU-423 NHzH[XJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXyS4FKSzVyPUKuPFkzPDJizszN NVfNe|RYW0GQR1XS
NCI-H1048 NEjJWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJwOU[4OlUh|ryP NED2fXdUSU6JRWK=
GR-ST MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrJeGtKSzVyPUOuNFQ3OTFizszN MX\TRW5ITVJ?
EoL-1- MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPtTWM2OD1|LkC3NFU5KM7:TR?= Mnr2V2FPT0WU
HuH-7 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTNwMEm0OlQh|ryP NXrGfVI{W0GQR1XS
OS-RC-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3LTWM2OD1|LkGxNVkh|ryP NUe5WGp2W0GQR1XS
EW-3 M365VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjrVZEzUUN3ME2zMlE6PTJ7IN88US=> MXvTRW5ITVJ?
NCI-H747 M37SO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfsepNKSzVyPUOuNlA3QTRizszN MmX1V2FPT0WU
EW-16 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\XeJBKSzVyPUOuNlE5PzlizszN NGDUW2FUSU6JRWK=
DOK NF3ocGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNwMkK4OVkh|ryP M2D5WnNCVkeHUh?=
HCC2157 NWnKR4tlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XhfGlEPTB;Mz6zPFE4QSEQvF2= NEjHPWJUSU6JRWK=
OVCAR-3 Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fH[GlEPTB;Mz60NFc5PiEQvF2= NH;DR41USU6JRWK=
NCI-H1623 NF;5NGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPYTppKSzVyPUOuOFEzOjRizszN M2[z[3NCVkeHUh?=
H4 MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNwNEW2NlYh|ryP M3LUOXNCVkeHUh?=
SW1710 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwNE[2O|gh|ryP Mnv0V2FPT0WU
RT-112 M4PVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHBV5A2UUN3ME2zMlUzOzh6IN88US=> NF7iPZZUSU6JRWK=
DMS-114 M{TmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfveFdKSzVyPUOuOlIzPzhizszN M1fHSnNCVkeHUh?=
AN3-CA MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r0[GlEPTB;Mz62NlQ2PiEQvF2= NV7PdopLW0GQR1XS
KNS-62 M1TjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNwNkOzN|gh|ryP NGL3dZdUSU6JRWK=
SJRH30 NH3kb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7tTWM2OD1|Lk[5NVIzKM7:TR?= NE[1c5ZUSU6JRWK=
G-402 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES5ZWtKSzVyPUOuO|A4OTFizszN NG\hS4NUSU6JRWK=
MHH-PREB-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvFNFFkUUN3ME2zMlczODN6IN88US=> NYjvR3g6W0GQR1XS
P30-OHK MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f5OWlEPTB;Mz64NFk4PiEQvF2= MYjTRW5ITVJ?
RVH-421 M4\FTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XoS2lEPTB;Mz64NVc5QCEQvF2= NHTtVHdUSU6JRWK=
LU-134-A M1vmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTNwOEi0Nlgh|ryP MYLTRW5ITVJ?
ECC10 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILpcmlKSzVyPUOuPVM3OjJizszN M1y5WnNCVkeHUh?=
TGW MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPrcVYzUUN3ME20MlAzOzB3IN88US=> M1nj[3NCVkeHUh?=
MLMA MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDxNpI{UUN3ME20MlAzQTZ4IN88US=> MoTYV2FPT0WU
SCC-25 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvuTWM2OD12LkC2OVY3KM7:TR?= MnKyV2FPT0WU
TYK-nu NGe1SI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP1TWM2OD12LkC5OVM1KM7:TR?= Mo\0V2FPT0WU
LAMA-84 MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITQV4pKSzVyPUSuNVQyQTFizszN M1vs[3NCVkeHUh?=
Calu-3 NInQRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGwTWM2OD12LkK0OFE3KM7:TR?= MUjTRW5ITVJ?
NCI-H460 NITwWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTRwMk[0OFMh|ryP MXLTRW5ITVJ?
EGI-1 NFPYXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRwM{e3O|gh|ryP NHezcnhUSU6JRWK=
NCI-H292 Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTRwM{ixOFYh|ryP MVnTRW5ITVJ?
HCE-T NIO3bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnQTWM2OD12LkSxOVc6KM7:TR?= NFnOWHZUSU6JRWK=
EW-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnIO49KSzVyPUSuOFE5OzhizszN NE\mdnZUSU6JRWK=
ATN-1 NUXrc5hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTUT4hKSzVyPUSuOFQ{ODRizszN MluxV2FPT0WU
NB5 NHz3bVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj6S5hKSzVyPUSuOVM3QTdizszN MkTBV2FPT0WU
KLE MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3UZZhKSzVyPUSuO|AyQThizszN NIfPcmNUSU6JRWK=
CAL-39 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrnPZNKSzVyPUSuO|IyPDZizszN MlzmV2FPT0WU
TI-73 M2fjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTRwOEC2NFkh|ryP MVXTRW5ITVJ?
HO-1-N-1 NV\0eIZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T4XGlEPTB;ND65OFIh|ryP MY\TRW5ITVJ?
786-0 NHzEWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPBTWM2OD12Lkm0Olc{KM7:TR?= MonWV2FPT0WU
SK-N-DZ MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTRwOU[xOFIh|ryP Mm\SV2FPT0WU
NCI-H446 M4TKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjBc29KSzVyPUWuNlAxODlizszN MYjTRW5ITVJ?
ETK-1 NFrVWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTVwMkGxOlUh|ryP MmLTV2FPT0WU
BT-20 M37zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoflTWM2OD13LkKxN|U{KM7:TR?= MojoV2FPT0WU
MEL-HO MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTVwM{ezN|Yh|ryP Mkn1V2FPT0WU
CAL-27 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3vb4RKSzVyPUWuOFY{OzlizszN NYrGSIU6W0GQR1XS
SW872 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[xVGVKSzVyPUWuOVk1OjhizszN NGPWXo1USU6JRWK=
RPMI-2650 NHHvTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3QTWM2OD13Lk[2NVk6KM7:TR?= MnK1V2FPT0WU
PFSK-1 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTVwN{K3N|Ih|ryP NFLISYhUSU6JRWK=
SF295 NH23SXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf4Xo1KSzVyPUWuPFA3OzNizszN Ml;HV2FPT0WU
Becker M363d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO0XllLUUN3ME21Mlg3PDd{IN88US=> Mlj0V2FPT0WU
Saos-2 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XxT2lEPTB;NT64OlU{KM7:TR?= M{X2OXNCVkeHUh?=
SK-OV-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;5d2lEPTB;NT65PVgyPiEQvF2= MXvTRW5ITVJ?
VMRC-RCZ MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTZwMEi3O|Mh|ryP NX3wNVlmW0GQR1XS
EW-22 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWzdJZKSzVyPU[uNVk3PDlizszN Mk\NV2FPT0WU
BT-474 NVrIOIFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzSOnZbUUN3ME22MlI{OyEQvF2= MWDTRW5ITVJ?
BFTC-909 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZwM{CzOFUh|ryP NYH5PYxZW0GQR1XS
NB12 NXvNWW5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni4TWM2OD14LkO5NFcyKM7:TR?= MYrTRW5ITVJ?
D-263MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzPTWM2OD14LkS1NVY6KM7:TR?= NV32NWFVW0GQR1XS
SNB75 NVPkd4cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTZwNkCxOFMh|ryP NIPCdHdUSU6JRWK=
A704 NY\jWpBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfDOm9KSzVyPU[uOlMxPiEQvF2= MVnTRW5ITVJ?
NCI-H1693 NXW2dHJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfhTVd7UUN3ME22MlY{PjB2IN88US=> NXzVVFhkW0GQR1XS
LN-405 NHfJbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXXdZlKSzVyPU[uO|k3PzJizszN NYnjN5NtW0GQR1XS
CHL-1 NIW0VXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17VeGlEPTB;Nj64NFA4QSEQvF2= MXHTRW5ITVJ?
A498 M3LXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTZwOEG5OlEh|ryP NGTLO29USU6JRWK=
TE-12 NGHRZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTZwOEO4NVch|ryP M3LWRXNCVkeHUh?=
TE-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PHe2lEPTB;Nj65N|A{QCEQvF2= M122OHNCVkeHUh?=
AU565 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[4XnljUUN3ME22Mlk3QTV5IN88US=> NUm5bJh3W0GQR1XS
RD MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hq[2lEPTB;Nj65PFI5PCEQvF2= NF:4eJNUSU6JRWK=
SW1463 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[yTWM2OD15LkGxNVY5KM7:TR?= MV\TRW5ITVJ?
LU-99A NFnKSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTdwMUSzNlIh|ryP MX3TRW5ITVJ?
NCI-H28 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTydIZKSzVyPUeuNlkzPCEQvF2= NFPtdIxUSU6JRWK=
MC-IXC NWC2eZNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILic49KSzVyPUeuOFg2PzZizszN M1rUOXNCVkeHUh?=
GP5d MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTdwNEi3OlQh|ryP MVzTRW5ITVJ?
GB-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHIR5FKSzVyPUeuOVQ5ODRizszN M1fjZXNCVkeHUh?=
CAL-33 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnSfGlEUUN3ME23MlY3OjN|IN88US=> MnzKV2FPT0WU
MSTO-211H MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPXTWM2OD15Lk[3N|M3KM7:TR?= MUTTRW5ITVJ?
TE-5 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH2TWM2OD15Lke5N|M1KM7:TR?= MUTTRW5ITVJ?
D-566MG NXiw[mxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TnSGlEPTB;OD6wOFQzQSEQvF2= M3;MOXNCVkeHUh?=
JVM-3 NGPQ[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HUXmlEPTB;OD6xOVI3QCEQvF2= NEDOO|lUSU6JRWK=
T98G M1XXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRThwMUiwOlch|ryP M{izXnNCVkeHUh?=
HCC1954 NGjVTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;GTWQ6UUN3ME24MlQ2OTB2IN88US=> NEnOb2VUSU6JRWK=
SF126 NWXQNo5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHuTWM2OD16LkS1PVM3KM7:TR?= M2e2OXNCVkeHUh?=
LB996-RCC NU\RWmNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRThwNUOyOVch|ryP MYTTRW5ITVJ?
SKG-IIIa MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n0eGlEPTB;OD62N|A3QSEQvF2= M2TQfXNCVkeHUh?=
NCI-SNU-1 NELPXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRThwNkS2OFMh|ryP M3XjcXNCVkeHUh?=
LB771-HNC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GzZmlEPTB;OD62OFY6PiEQvF2= M3uy[nNCVkeHUh?=
SCC-4 M1f5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHOTWM2OD16Lk[4NlE6KM7:TR?= MlX5V2FPT0WU
CAMA-1 MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPSU2lIUUN3ME24Mlc4OTR4IN88US=> MlfkV2FPT0WU
D-502MG NGC3cYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXTTWM2OD16Lke4OlI6KM7:TR?= M4PrbnNCVkeHUh?=
ESS-1 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX6TWM2OD16Lki4O|A1KM7:TR?= MoHnV2FPT0WU
HEC-1 MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHRVmpKSzVyPUiuPFk5PjZizszN M3jVR3NCVkeHUh?=
NB10 M37QU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3KTWM2OD17LkCyNlI1KM7:TR?= NGS3VFJUSU6JRWK=
8505C NG\tN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUSxboJnUUN3ME25MlA1OjN{IN88US=> NHXn[ZVUSU6JRWK=
EFO-27 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HLWWlEPTB;OT6xOlQyOiEQvF2= MYTTRW5ITVJ?
HN M2XGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPZOlNKSzVyPUmuNVY3OjhizszN NYTacGVLW0GQR1XS
DSH1 NFLiOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\0TWM2OD17LkKwPFch|ryP M3j5OHNCVkeHUh?=
NBsusSR NXfYWIZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny4TWM2OD17LkK3OFAzKM7:TR?= NHOzVndUSU6JRWK=
LS-123 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPJTWM2OD17LkOxO|YyKM7:TR?= M4T1NHNCVkeHUh?=
SHP-77 M2HZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKxToRKSzVyPUmuN|k6OzVizszN MnTiV2FPT0WU
ACN M2XueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvDbGZKSzVyPUmuOVMzPzdizszN M1vBN3NCVkeHUh?=
U251 NYXaXJJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTlwNkW1OFQh|ryP Mn\OV2FPT0WU
A431 NHXhW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\aems1UUN3ME25MlgxOjN6IN88US=> NFjmOYtUSU6JRWK=
5637 M325UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq1U3NTUUN3ME25Mlg1QTh2IN88US=> MmmyV2FPT0WU
MDA-MB-157 M{\UdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr4NG1KSzVyPUmuPVI5PzhizszN NHv1NnJUSU6JRWK=
A101D MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTlwOUm5O|Qh|ryP NWHWSVZ3W0GQR1XS
YKG-1 NXLmb4tsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFyLkKwNFYh|ryP MUPTRW5ITVJ?
LAN-6 M1zLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi1TWM2OD1zMD6yNVY1KM7:TR?= NEnEOZFUSU6JRWK=
OVCAR-5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFyLkK0N|Mh|ryP Ml3yV2FPT0WU
A549 NX\pdXRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TWemlEPTB;MUCuN|k4OyEQvF2= MVjTRW5ITVJ?
no-11 M{L6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP0Rmd2UUN3ME2xNE41OzV|IN88US=> M1u1WXNCVkeHUh?=
SF539 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;wTWM2OD1zMD65NFQyKM7:TR?= MUnTRW5ITVJ?
A388 M1TnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO0Vm92UUN3ME2xNU4{QDl5IN88US=> NIfj[m9USU6JRWK=
DEL MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PXTWlEPTB;MUGuOFI1KM7:TR?= MWfTRW5ITVJ?
SW954 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DTZ2lEPTB;MUGuOFY3QCEQvF2= NH3o[VNUSU6JRWK=
TK10 NFHmd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq1OJFKSzVyPUGxMlUzPzFizszN NVXOTlJjW0GQR1XS
SW756 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzYfY1vUUN3ME2xNU42Ojl2IN88US=> MlXVV2FPT0WU
PC-3 NWLLPGRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFzLkW3OlQh|ryP M1jTPHNCVkeHUh?=
ONS-76 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFzLk[zOkDPxE1? Ml7oV2FPT0WU
A427 M2T3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDMTWM2OD1zMT63NFk{KM7:TR?= NUHlPJlIW0GQR1XS
MEG-01 NULhflJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPi[4JKSzVyPUGxMlc2ODlizszN MULTRW5ITVJ?
BB30-HNC NF\CeYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHlUJJKSzVyPUGxMlc6QDJizszN MYHTRW5ITVJ?
NCI-H1299 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXTUIlKSzVyPUGxMlgxQTNizszN NX;0doFOW0GQR1XS
GCT M1ezU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFzLkiyNlgh|ryP M{PN[3NCVkeHUh?=
D-247MG M4rZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nLN2lEPTB;MUGuPVY3OyEQvF2= Mnf5V2FPT0WU
CFPAC-1 NVK0NIlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X4U2lEPTB;MUGuPVc5OiEQvF2= NGXKb5NUSU6JRWK=
EKVX MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\QZ5Y5UUN3ME2xNk4xOzF|IN88US=> MYnTRW5ITVJ?
CAL-51 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF{LkC3NVYh|ryP NH;oPJVUSU6JRWK=
BB49-HNC NH;MWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LlOWlEPTB;MUKuNVE4PyEQvF2= MkT4V2FPT0WU
RPMI-7951 NXX6cnpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHkbZZKSzVyPUGyMlE5PTRizszN NUXEbphRW0GQR1XS
RH-1 NYLMSJRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHKfpFKSzVyPUGyMlIyQDRizszN NV;3Xno{W0GQR1XS
BCPAP M{m3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH1TVR[UUN3ME2xNk41PzR7IN88US=> Mm\5V2FPT0WU
GCIY NVriW3FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFryV4VKSzVyPUGyMlUzODlizszN M{\VOHNCVkeHUh?=
KNS-81-FD NWe5cW9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jlOWlEPTB;MUKuOVg3QSEQvF2= NV3E[HdGW0GQR1XS
KYSE-140 MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF{Lki1PVUh|ryP MmXwV2FPT0WU
Ca-Ski M1zxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7xTWM2OD1zMj65NFQyKM7:TR?= NV73dZVZW0GQR1XS
TGBC1TKB M{\CW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF{LkmxNVUh|ryP NHXqOlFUSU6JRWK=
HCC1187 NVHORpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7YTWM2OD1zMz6xPVEzKM7:TR?= MmfRV2FPT0WU
SJSA-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\2TWM2OD1zMz6yN|I4KM7:TR?= MXXTRW5ITVJ?
CTV-1 NFfGPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF|LkO0OUDPxE1? Mk\RV2FPT0WU
WM-115 NV3QfXU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPkXnlKSzVyPUGzMlY1QDNizszN MlX3V2FPT0WU
CHP-212 NXTHZpVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[wU4pKSzVyPUGzMlk4OzlizszN M3;Zc3NCVkeHUh?=
SCC-15 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[zVpVKSzVyPUGzMlk4PzVizszN NYW2ZYQ3W0GQR1XS
BPH-1 NVjTXJdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPSdpRKUUN3ME2xOE4yPjZ2IN88US=> NGnTOWxUSU6JRWK=
SW780 M3POV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTiTWM2OD1zND61NFI2KM7:TR?= NVLweGh[W0GQR1XS
NCI-H2291 M3TOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF2LkW4O|gh|ryP MWTTRW5ITVJ?
JEG-3 M1vMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF2Lk[zNlYh|ryP MorWV2FPT0WU
CAL-120 Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD3ZnZKSzVyPUG0MlcxOjdizszN Ml3sV2FPT0WU
NCI-H23 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjDUFNKSzVyPUG0Mlc6QTdizszN MnKxV2FPT0WU
MS-1 NWrvS|BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PDc2lEPTB;MUSuPVYyOSEQvF2= M2W3[3NCVkeHUh?=
PC-14 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF2Lkm2OVQh|ryP M1y3XXNCVkeHUh?=
D-283MED M4L4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfmbpNKSzVyPUG1MlAyOTFizszN NGnsOJlUSU6JRWK=
OE19 NWXMfm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjrT3dtUUN3ME2xOU4yPTRzIN88US=> NIHtSZVUSU6JRWK=
CAS-1 NVjFT2JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\IfYt5UUN3ME2xOU41OTh2IN88US=> NX3VcYJiW0GQR1XS
NCI-H727 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vpPGlEPTB;MUWuOFIzOSEQvF2= NWjnW2lJW0GQR1XS
SiHa M1rBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjFZZBKSzVyPUG1Mlc2QTRizszN NWrN[4o4W0GQR1XS
BFTC-905 NHn0c2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37CemlEPTB;MUWuO|Y6PCEQvF2= NUnSeJZEW0GQR1XS
MDA-MB-453 M17pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrKbYZPUUN3ME2xOk4yPjR{IN88US=> NH;RWXFUSU6JRWK=
HuP-T3 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jKV2lEPTB;MU[uOlM4OyEQvF2= NYfLe2JIW0GQR1XS
SK-LU-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXSdVhKSzVyPUG2MlY6PTZizszN Mkn2V2FPT0WU
Detroit562 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHTUVBKSzVyPUG2Mlc{OThizszN MXnTRW5ITVJ?
HCC1569 NXHMXpBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPSTWM2OD1zNj64N|M4KM7:TR?= NXzwOoh1W0GQR1XS
SK-MES-1 NH3tOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn22TWM2OD1zNj64OFE6KM7:TR?= NHjnfVJUSU6JRWK=
BB65-RCC M33Qc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWy[VhKSzVyPUG3MlA1PzlizszN NIDXS3lUSU6JRWK=
LOXIMVI NEfTbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r1dWlEPTB;MUeuNFcxPyEQvF2= MX\TRW5ITVJ?
SW1783 M2riSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj5TWM2OD1zNz6xNlgh|ryP MVTTRW5ITVJ?
NH-12 NF7lRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13wbGlEPTB;MUeuN|MxOyEQvF2= NG\IfXBUSU6JRWK=
UACC-257 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\IZ2tmUUN3ME2xO{42PTF{IN88US=> MWfTRW5ITVJ?
KOSC-2 M164eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\Rd3pKSzVyPUG3MlY4PTdizszN MmLTV2FPT0WU
KG-1 M33rfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjVVmxKSzVyPUG3MlY6OzdizszN MV3TRW5ITVJ?
M059J NGXKVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPYfoJKSzVyPUG3MlcxOyEQvF2= NXWzcVhzW0GQR1XS
MHH-NB-11 M37NTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfRVlVFUUN3ME2xO{46Pjd|IN88US=> MXvTRW5ITVJ?
EW-1 M4X4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF6LkGzPFIh|ryP NIe2dohUSU6JRWK=
CAL-85-1 M{jJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLTTWM2OD1zOD6yN|U4KM7:TR?= MUHTRW5ITVJ?
639-V NYG4cW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;SVWNOUUN3ME2xPE4{OzV2IN88US=> MXnTRW5ITVJ?
C32 M4POR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfiTWM2OD1zOD60O|I4KM7:TR?= MY\TRW5ITVJ?
KM-H2 Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPZTWM2OD1zOD61NlMzKM7:TR?= M{DDWnNCVkeHUh?=
A253 MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHyV482UUN3ME2xPE44Ojh4IN88US=> NXrMO4NyW0GQR1XS
NCI-N87 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF6LkmwNFgh|ryP MWDTRW5ITVJ?
8-MG-BA M{fZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPYTWM2OD1zOT6wOlQ3KM7:TR?= NWHWSpg{W0GQR1XS
GI-ME-N NGDYNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDCTWM2OD1zOT6xOVQ3KM7:TR?= MX\TRW5ITVJ?
8305C MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jPZ2lEPTB;MUmuNlI5PiEQvF2= M{DLXHNCVkeHUh?=
TE-8 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HIeGlEPTB;MUmuN|AzPCEQvF2= Ml\6V2FPT0WU
KYSE-270 NYLTSndST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnlOZVKSzVyPUKwMlAzOTdizszN M{TMNnNCVkeHUh?=
HL-60 NFnHTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nDU2lEPTB;MkCuNFk1OSEQvF2= MVrTRW5ITVJ?
Mo-T MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJyLkG2OlUh|ryP NXPH[4R2W0GQR1XS
NCI-H1355 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL2b5NKSzVyPUKwMlM{PzRizszN NHP3ZXBUSU6JRWK=
HT-1080 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vIXWlEPTB;MkCuOVQ6PyEQvF2= NWO1O2JZW0GQR1XS
MIA-PaCa-2 M{ThTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJyLk[4PFMh|ryP M4q0OnNCVkeHUh?=
NCI-H441 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DueGlEPTB;MkCuO|M4QSEQvF2= MoHxV2FPT0WU
LCLC-97TM1 M4f6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zJV2lEPTB;MkCuPFE{PCEQvF2= MWfTRW5ITVJ?
HT-3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHhTWM2OD1{MT61OlMyKM7:TR?= NGjSTmFUSU6JRWK=
22RV1 NYizdGk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2frT2lEPTB;MkGuOVY5PSEQvF2= NW\URmtqW0GQR1XS
LK-2 NV;CTWFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvseYpKSzVyPUKxMlU6PTNizszN NWWyVXlXW0GQR1XS
CW-2 M{HLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f4PWlEPTB;MkGuOlA3QSEQvF2= NEnsU5JUSU6JRWK=
KYSE-510 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nSUGlEPTB;MkGuOlA6PSEQvF2= MXzTRW5ITVJ?
CGTH-W-1 NHq1[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{GxT2lEPTB;MkGuO|E3PiEQvF2= M2TKZnNCVkeHUh?=
NCI-H661 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ{LkCzOEDPxE1? NHz2N2hUSU6JRWK=
KU-19-19 Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\mSGlEPTB;MkKuNVY6PyEQvF2= NF2wZXBUSU6JRWK=
NCI-H2122 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;wNYFDUUN3ME2yNk4zPDN{IN88US=> MYjTRW5ITVJ?
NCI-H526 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ{LkO4PVUh|ryP M1rZ[3NCVkeHUh?=
NCI-H1650 M{WxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nSfWlEPTB;MkKuO|Y1KM7:TR?= MoLFV2FPT0WU
AM-38 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ{Lki2PFkh|ryP MYrTRW5ITVJ?
NCI-H2405 NEf3SohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ|LkK1N|Mh|ryP MmHZV2FPT0WU
M14 M3;6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LHfGlEPTB;MkOuOFA5QCEQvF2= MVHTRW5ITVJ?
ES4 M164VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzITWM2OD1{Mz60NlMzKM7:TR?= M2e2ZnNCVkeHUh?=
DJM-1 NUW1PJpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrUVFE{UUN3ME2yN{42OjN2IN88US=> MV\TRW5ITVJ?
S-117 NIPHWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rpcmlEPTB;MkOuO|Y2OSEQvF2= NWjCSIdiW0GQR1XS
MZ2-MEL NUPaNHB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\ITWM2OD1{Mz63O|U6KM7:TR?= M{Dl[HNCVkeHUh?=
SK-MEL-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonYTWM2OD1{Mz64NVM{KM7:TR?= MkTQV2FPT0WU
HCC1806 MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX2UWJIUUN3ME2yN{45PzB7IN88US=> NITtXJdUSU6JRWK=
NMC-G1 M4fNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH21UGdKSzVyPUK0MlIzOjZizszN MXfTRW5ITVJ?
DK-MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;KXIRKSzVyPUK0MlI6PCEQvF2= MkHuV2FPT0WU
SK-N-FI NWC3bIJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXqcnJ3UUN3ME2yOE4{OzB{IN88US=> NVrtd4R3W0GQR1XS
KINGS-1 NIq1SYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi5XGw5UUN3ME2yOE41QDd2IN88US=> MWnTRW5ITVJ?
HCC2998 M2XN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfFUZRKSzVyPUK0MlQ5QDVizszN MonLV2FPT0WU
ALL-PO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C2[mlEPTB;MkSuOlE6KM7:TR?= NVH3cnZwW0GQR1XS
MPP-89 M4G1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ3LkC0OVgh|ryP Ml3DV2FPT0WU
NCI-H2342 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFyzcIRKSzVyPUK1MlE6PTNizszN MkTDV2FPT0WU
TE-1 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe0dnZKSzVyPUK1MlM2PjNizszN MWPTRW5ITVJ?
RH-18 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TCTWlEPTB;MkWuOVkyQCEQvF2= MWnTRW5ITVJ?
HT-1376 Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ3Lk[0OlUh|ryP MnzmV2FPT0WU
U-2-OS MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ3Lk[4PFgh|ryP MYLTRW5ITVJ?
BT-549 M4DKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:0RmlEPTB;MkWuPVAyOSEQvF2= M2W1WXNCVkeHUh?=
NCI-H1755 NHiyPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7nRm1KSzVyPUK1Mlk6PDVizszN NVPvbY1IW0GQR1XS
EW-13 M3fadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HUc2lEPTB;Mk[uNFI4PCEQvF2= MXnTRW5ITVJ?
NB13 NEfW[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7yRZF4UUN3ME2yOk4xQTR7IN88US=> NWjLdoNOW0GQR1XS
NUGC-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTsTWM2OD1{Nj6yNVA{KM7:TR?= M4HsXHNCVkeHUh?=
GMS-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K0S2lEPTB;Mk[uNlM2OyEQvF2= NW\ZfG1IW0GQR1XS
CHP-134 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v5XWlEPTB;Mk[uN|g3PyEQvF2= NULucHVDW0GQR1XS
SW962 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\HTWM2OD1{Nj61NFIyKM7:TR?= NYK4Z|R5W0GQR1XS
SNU-449 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\ITWM2OD1{Nz6wPFA{KM7:TR?= NV\EVWc6W0GQR1XS
HuP-T4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ5LkC4O|kh|ryP MXzTRW5ITVJ?
SW948 NXzPSIFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LRWGlEPTB;MkeuNVM1PCEQvF2= NUT0cnpxW0GQR1XS
NCI-H226 MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XOeWlEPTB;MkeuOFU4QCEQvF2= NUThVYRYW0GQR1XS
SK-PN-DW M3G0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjjTWM2OD1{Nz62NFEzKM7:TR?= M{TQNXNCVkeHUh?=
GI-1 NVPtcGhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEizXIFKSzVyPUK3MlczOSEQvF2= M3znRnNCVkeHUh?=
CAL-12T NGnKb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJ6LkGxNVIh|ryP NVLKU4k2W0GQR1XS
YAPC M2jEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnxdGdKSzVyPUK4MlI2PjRizszN NGTwVlVUSU6JRWK=
SNU-C2B Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HpVWlEPTB;MkiuNlk3PCEQvF2= MVTTRW5ITVJ?
RCC10RGB NIn5U3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTRTIh4UUN3ME2yPE42PDF5IN88US=> MkexV2FPT0WU
ES7 MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW1PHBKSzVyPUK5MlE1PjVizszN NI\TbXRUSU6JRWK=
PANC-03-27 NWm3eYxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[4TWM2OD1{OT60OFQh|ryP NUK5coZpW0GQR1XS
ES6 M2TTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV73UYw{UUN3ME2yPU45OTV5IN88US=> NI\qRm5USU6JRWK=
HT-1197 NGXPdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHztOnFKSzVyPUOwMlA2QThizszN M1frTXNCVkeHUh?=
ZR-75-30 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XKb2lEPTB;M{CuNlM5OyEQvF2= MlHPV2FPT0WU
DB MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPZdm1nUUN3ME2zNE41QTR{IN88US=> NIjVSWZUSU6JRWK=
OCI-AML2 NFfGb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ITWM2OD1|MT6wOlkh|ryP Mn3EV2FPT0WU
NCI-H2170 MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC3TGJMUUN3ME2zNU45PTF4IN88US=> NVjZTZl4W0GQR1XS
IST-MES1 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfuTWM2OD1|Mj6yPFk4KM7:TR?= MULTRW5ITVJ?
769-P NWnXeGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTN{LkO2OFEh|ryP MX\TRW5ITVJ?
COR-L23 NHzFOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jPXGlEPTB;M{KuPVA4OyEQvF2= M1vpXnNCVkeHUh?=
SW626 NInWUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknGTWM2OD1|Mz6xO|c3KM7:TR?= Mke1V2FPT0WU
LU-139 NI\uN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTN|Lk[2NFUh|ryP NEC3TpVUSU6JRWK=
HT-144 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN|Lki2N{DPxE1? MlTtV2FPT0WU
CaR-1 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTN|Lkm4NlIh|ryP M1zaN3NCVkeHUh?=
OE33 MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkexTWM2OD1|ND6yPFU2KM7:TR?= MUTTRW5ITVJ?
COLO-800 NYn1SXhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXTTWM2OD1|ND6zOlQ4KM7:TR?= MV7TRW5ITVJ?
NB14 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTN2LkS2PFQh|ryP NGniOVVUSU6JRWK=
KURAMOCHI NXPwfW4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOwWoFKSzVyPUO2MlEyQThizszN M{nOdXNCVkeHUh?=
SW48 NEXiV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTNTWM2OD1|Nj6yOFc1KM7:TR?= NILKZmhUSU6JRWK=
Daoy NUDufo14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTN4Lk[1N|gh|ryP M2XrUXNCVkeHUh?=
TGBC24TKB M1u2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTN4Lk[3JO69VQ>? MoH4V2FPT0WU
DU-4475 Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zwNmlEPTB;M{[uPVA{OyEQvF2= NE\PSFhUSU6JRWK=
SW1417 NXXGTFlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XG[WlEPTB;M{iuNFU2OiEQvF2= MUHTRW5ITVJ?
EFO-21 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XaV2lEPTB;M{iuPVM1QSEQvF2= NWe1foQxW0GQR1XS
MG-63 NYjIZ45nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ywXGlEPTB;M{muN|QzPCEQvF2= M{HVNnNCVkeHUh?=
LC-2-ad NHjMVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXUTWM2OD1|OT61OVEzKM7:TR?= NWTZUHZ6W0GQR1XS
NOMO-1 M3XMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3pTWM2OD1|OT64Nlc1KM7:TR?= NIfidmdUSU6JRWK=
COLO-741 NEXiO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTRyLkGzNFQh|ryP NGfhdWFUSU6JRWK=
BxPC-3 NEDzWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[2TWM2OD12MD61Olg3KM7:TR?= MlfuV2FPT0WU
HSC-2 NX\SToRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fKeWlEPTB;NECuPVEyOyEQvF2= NHLzO25USU6JRWK=
UMC-11 NYLNfYpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M121TWlEPTB;NEGuNlY{KM7:TR?= NH\R[YJUSU6JRWK=
HCC1937 NVXwWJlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonHTWM2OD12Mj63PFQ{KM7:TR?= MkO4V2FPT0WU
Calu-6 MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnHTWM2OD12Mz6yN|gzKM7:TR?= MYfTRW5ITVJ?
NCI-H1573 NVzEdlYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTR|LkO0O|ch|ryP MlfmV2FPT0WU
SK-N-AS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TZWGlEPTB;NEOuOlAyQSEQvF2= NV;hcoFnW0GQR1XS
PSN1 NUOwfotvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTR3LkK1OFgh|ryP MVjTRW5ITVJ?
TE-11 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTR3LkS4OFIh|ryP NHmyPHpUSU6JRWK=
NCI-H1155 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTR3Lki5Olch|ryP M2i3ZnNCVkeHUh?=
KM12 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS4UGN7UUN3ME20OU46ODd4IN88US=> M{PyfnNCVkeHUh?=
RO82-W-1 NGi2fHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTR4Lkm4NlIh|ryP MnX3V2FPT0WU
SW1573 MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjTcI1KSzVyPUS3MlM4OzZizszN NYf1fY5mW0GQR1XS
CAKI-1 M1G5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf3VFJKSzVyPUS4MlI5PDVizszN MYLTRW5ITVJ?
U-118-MG NH7UeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPMNZpvUUN3ME20PE4{PzB{IN88US=> NH3VcoJUSU6JRWK=
KYSE-520 NX60PYR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGwTWM2OD12OD60NFE3KM7:TR?= NYTJ[I9qW0GQR1XS
HT55 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny2TWM2OD12OT6xOFc1KM7:TR?= MYnTRW5ITVJ?
ChaGo-K-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GyZmlEPTB;NEmuOFc6OyEQvF2= Ml7SV2FPT0WU
IA-LM NUPsfJoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:xW5ZKSzVyPUW0MlY{OjJizszN NVnocIprW0GQR1XS
UACC-62 NHG2dmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zj[GlEPTB;NUWuNVA1PiEQvF2= MkDlV2FPT0WU
MKN7 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTScppYUUN3ME21Ok4xOjh3IN88US=> NGLXZ2JUSU6JRWK=
HPAF-II NWXZOndpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jBR2lEPTB;NU[uOFA4OyEQvF2= MV;TRW5ITVJ?
NTERA-S-cl-D1 M2L0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLqTWM2OD13Nz63O|gh|ryP NYP4Ulg{W0GQR1XS
FTC-133 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\wSGhKSzVyPUW4MlA6PjlizszN Mnq3V2FPT0WU
MHH-ES-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTV6LkS4NVQh|ryP MnPjV2FPT0WU
JVM-2 NUTKe2xxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rEbmlEPTB;NUiuPVUxPiEQvF2= NFz4cJZUSU6JRWK=
TCCSUP M2jqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TGNmlEPTB;NUmuOVI4QSEQvF2= NEjzeo5USU6JRWK=
COLO-824 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPYbY1YUUN3ME22NE4xPzF7IN88US=> M3vOTXNCVkeHUh?=
647-V MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrFTWM2OD14MD6xN|Q4KM7:TR?= MmT6V2FPT0WU
HD-MY-Z NWnwT2NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M365PWlEPTB;NkCuOVI6PCEQvF2= M1nR[HNCVkeHUh?=
LS-411N NGS0Z3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTZzLkO5NFMh|ryP NIK1bI5USU6JRWK=
NCI-H596 MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTHTWM2OD14Mj63OFk3KM7:TR?= M2LqbHNCVkeHUh?=
C-33-A MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTZ2LkC5OVch|ryP MYnTRW5ITVJ?
BHY M{fVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXvO3RKSzVyPU[0MlEzPDVizszN M1X3fXNCVkeHUh?=
KGN NGT3blRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnydlREUUN3ME22OE42PTF2IN88US=> NYKzfJVqW0GQR1XS
NCI-H1092 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PFc2lEPTB;NkWuNFA6PSEQvF2= NGLQT4JUSU6JRWK=
MZ1-PC NYXDbWxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzYTWM2OD14NT61OlQ6KM7:TR?= MlfQV2FPT0WU
LB831-BLC M1XWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknnTWM2OD14NT64OFgyKM7:TR?= MVPTRW5ITVJ?
SW620 NW\ufGxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;pSmlEPTB;Nk[uNlA{QSEQvF2= M3\zUHNCVkeHUh?=
HuO-3N1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLZdJQ6UUN3ME22PE4{OjN6IN88US=> NFvGfY1USU6JRWK=
SK-HEP-1 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLJTWM2OD14OT65OFg3KM7:TR?= NFvESYNUSU6JRWK=
LCLC-103H MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfSeYNGUUN3ME23NE43PzB3IN88US=> NGXz[HRUSU6JRWK=
KYSE-70 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXwRWhoUUN3ME23NE44QDN3IN88US=> NVu0Oo95W0GQR1XS
Mewo MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPCb3lKSzVyPUexMlUxPSEQvF2= M{HNbXNCVkeHUh?=
COLO-668 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[3TWM2OD15MT64OFUyKM7:TR?= M3XSU3NCVkeHUh?=
NCI-H522 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFywSplKSzVyPUeyMlM1OTNizszN M1\aSXNCVkeHUh?=
NCI-H1437 Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITZbpZKSzVyPUe0MlQxPDhizszN MoK3V2FPT0WU
U-266 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrkTWM2OD15NT60OVE3KM7:TR?= M4e4bnNCVkeHUh?=
MC116 MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH3SVZKSzVyPUe1MlU4ODhizszN MnHNV2FPT0WU
PANC-10-05 NVu0Ro9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH75Z|BKSzVyPUe3MlQzPDNizszN MU\TRW5ITVJ?
KYSE-180 NG[5XmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rTcGlEPTB;N{euOVQ2PCEQvF2= Mmr5V2FPT0WU
JAR MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHkbFJKSzVyPUe5MlA2PDZizszN NXzINJhZW0GQR1XS
CAL-62 M2q5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorwTWM2OD16MD6wPVUh|ryP MYLTRW5ITVJ?
A3-KAW NFW2ZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRThyLkKxOVQh|ryP M1nMb3NCVkeHUh?=
PANC-08-13 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHJTWM2OD16MT6xO|Y5KM7:TR?= M13xV3NCVkeHUh?=
HSC-3 NFjsclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;JTWM2OD16Mz6zNFcyKM7:TR?= NFfoSnhUSU6JRWK=
HTC-C3 NFO0fGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HBdGlEPTB;OEOuOFcxOiEQvF2= MkLCV2FPT0WU
KY821 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLGTWM2OD16ND6wPFkzKM7:TR?= M3S4VHNCVkeHUh?=
DoTc2-4510 NILldppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT1WWNKSzVyPUi0MlIyQDVizszN NGrVR3ZUSU6JRWK=
NCI-H1581 NVrlS4p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[0TWM2OD16NT60OlQyKM7:TR?= M1rMXXNCVkeHUh?=
KARPAS-299 MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTh4LkG5O|ch|ryP NETSXFJUSU6JRWK=
IST-MEL1 NUTrV2lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTh4Lki4O|Ih|ryP NX;Tb4dPW0GQR1XS
KP-N-YS MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7ITWM2OD16OT65NFI5KM7:TR?= M{fEWXNCVkeHUh?=
KYSE-410 M1X2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzXTWM2OD17MT60NFQzKM7:TR?= NYG1Rnl5W0GQR1XS
TE-10 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP0TWM2OD17MT61OlEyKM7:TR?= M2fMXXNCVkeHUh?=
SK-MEL-1 NIfnSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHjTWM2OD17Mj65NVA3KM7:TR?= NETuUpdUSU6JRWK=
COLO-792 NXK1dpNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTl3LkK1OlQh|ryP MW\TRW5ITVJ?
SCH MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTl4LkO4O|ch|ryP NVPldnlrW0GQR1XS
NCI-H1792 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfzTWM2OD17Nj64PVkzKM7:TR?= M{jLNXNCVkeHUh?=
NCI-H2029 MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnacoNKSzVyPUm2Mlk2PjZizszN NFTQdFBUSU6JRWK=
SW684 NGH1VppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fjO2lEPTB;OUiuOlY2PCEQvF2= MU\TRW5ITVJ?
NCI-H209 NFz6bWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv5W5VnUUN3ME2xNFAvOTJzIN88US=> M2TyNnNCVkeHUh?=
HLE M{i3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFyNT6yPFIh|ryP NVvBSGRLW0GQR1XS
GOTO NXHCZpZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjXS5BKSzVyPUGwO{44PzdizszN MY\TRW5ITVJ?
NCI-H1793 MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFyOT6yPEDPxE1? MYDTRW5ITVJ?
D-392MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLkPIJmUUN3ME2xNVcvOzl6IN88US=> NYLjSWlbW0GQR1XS
SW1990 M4racmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7yTWM2OD1zMkCuPVUyKM7:TR?= MlHvV2FPT0WU
ML-2 NF35UmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3jOJI2UUN3ME2xNlEvPjd4IN88US=> MYXTRW5ITVJ?
NCI-H2452 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz6b3h1UUN3ME2xNlIvOjFizszN MYTTRW5ITVJ?
SK-MEL-30 NI\wbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF{Mz6yOFQh|ryP NIK3XXBUSU6JRWK=
SN12C NVfneWh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCxTWM2OD1zMkSuNVc3KM7:TR?= MV;TRW5ITVJ?
NCI-H1770 NYLYfXQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn2SIxpUUN3ME2xNlUvPTF2IN88US=> NWTtVVlxW0GQR1XS
SF268 M2HEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHGTWM2OD1zMk[uNVU5KM7:TR?= M{\Nd3NCVkeHUh?=
BALL-1 M4fTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3OSZhKSzVyPUGyOk4zOyEQvF2= M3:zPXNCVkeHUh?=
COLO-679 MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrBTWM2OD1zMk[uO|U{KM7:TR?= M1HKVXNCVkeHUh?=
A2780 M4m1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn1b|BqUUN3ME2xNlgvQTh6IN88US=> M1vleXNCVkeHUh?=
NCI-H1651 MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF|MT6yOFMh|ryP NWLJb|Q6W0GQR1XS
NCI-H2087 NUPYWVE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr6UYQ1UUN3ME2xN|EvPDh|IN88US=> NGXicFFUSU6JRWK=
U-87-MG NWm5T3d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlftTWM2OD1zM{OuOlA1KM7:TR?= Ml\UV2FPT0WU
LB2518-MEL NVnNXWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S5bGlEPTB;MUO1Mlk6OyEQvF2= NUTLbHk4W0GQR1XS
HCT-116 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL3bmpKSzVyPUGzO{4zOTdizszN NVLjZXg4W0GQR1XS
Ca9-22 NWDpT5lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn0TWM2OD1zM{muPFM{KM7:TR?= M3Xa[XNCVkeHUh?=
COR-L88 NUfWOpZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[1bZBjUUN3ME2xOFIvOTRizszN MoLUV2FPT0WU
CP50-MEL-B M1;UT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXflTHVuUUN3ME2xOFQvPTBzIN88US=> MknKV2FPT0WU
OVCAR-8 NIDyXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuwTlBEUUN3ME2xOFUvPjN4IN88US=> NXT5NpVlW0GQR1XS
SK-MEL-3 M4r3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PJZmlEPTB;MUS3Mlg4QCEQvF2= NUjCW4Y5W0GQR1XS
GT3TKB NI\GXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;je4RKSzVyPUG0PU46OjhizszN MVvTRW5ITVJ?
KYSE-450 NEPvbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPCcWdKSzVyPUG1NU42OzlizszN M4nn[3NCVkeHUh?=
CAPAN-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVyzb2pyUUN3ME2xOVMvODZ2IN88US=> NHK0W2VUSU6JRWK=
BEN NILhcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF3Mz65Nlgh|ryP NI\TPHNUSU6JRWK=
NCI-H1304 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTUTWM2OD1zNUSuOlk1KM7:TR?= MlLaV2FPT0WU
KU812 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33OU2lEPTB;MUW4MlY4PCEQvF2= M3XkXnNCVkeHUh?=
Capan-2 M{\3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfVeJo4UUN3ME2xOlAvPTV|IN88US=> Mn\3V2FPT0WU
A673 NU\3eoNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHoSG5KSzVyPUG2NU44ODVizszN MVvTRW5ITVJ?
SAS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HScWlEPTB;MU[yMlY4QCEQvF2= MoX5V2FPT0WU
NY NXGybnJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO3OYVFUUN3ME2xOlUvOzF2IN88US=> M{j3[HNCVkeHUh?=
HCE-4 M{nk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TzVWlEPTB;MU[2Mlg1PSEQvF2= NW\udG05W0GQR1XS
MDA-MB-231 Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHSTWM2OD1zN{euOVA{KM7:TR?= Mn;QV2FPT0WU
no-10 M2f3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3oTWM2OD1zN{iuNVM1KM7:TR?= MkXiV2FPT0WU
MZ7-mel M3G1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrvU5BuUUN3ME2xO|gvPDZ5IN88US=> MX\TRW5ITVJ?
NCI-H82 NFOw[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHryRWtKSzVyPUG4NE4yPjVizszN MkjuV2FPT0WU
CAL-72 NGPDZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrL[nNTUUN3ME2xPFUvODV2IN88US=> NFPFdm5USU6JRWK=
NCI-SNU-5 NXXXfZAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrITmxKSzVyPUG4Ok45PCEQvF2= Mn3CV2FPT0WU
OVCAR-4 M1rQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3XZ|dKSzVyPUG4PE4{OzNizszN NGTuOlBUSU6JRWK=
SCC-9 M2PBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF7MTFOwG0> NX7KVWRkW0GQR1XS
KYSE-150 MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLDTWM2OD1zOUGuPFg5KM7:TR?= MXHTRW5ITVJ?
HT-29 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\BXVVKSzVyPUKwNU4zOTJizszN MkG1V2FPT0WU
COLO-678 NVqzSohZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJyMT60OUDPxE1? MYPTRW5ITVJ?
NCI-H650 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJyMj6xNFMh|ryP M3WwUnNCVkeHUh?=
HuCCT1 M{\pSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzMTWM2OD1{MESuNlA5KM7:TR?= NXrxfGJ{W0GQR1XS
SW1116 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DUfWlEPTB;MkC3MlA4PyEQvF2= NYq1[YZXW0GQR1XS
DBTRG-05MG NUPhVWprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm0TWM2OD1{MEeuPVA6KM7:TR?= M3n1dXNCVkeHUh?=
SW982 M2rjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfje4JKSzVyPUKwO{46PDhizszN NYTXZ|hTW0GQR1XS
RCM-1 M3ezfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXvTWM2OD1{MUSuO|YzKM7:TR?= M2DtXHNCVkeHUh?=
COLO-320-HSR NYnMc2dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzoSnEyUUN3ME2yNVYvOTJ3IN88US=> NYf3botyW0GQR1XS
KNS-42 M2HIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TUOWlEPTB;MkG2MlU4PCEQvF2= NHzveZBUSU6JRWK=
C2BBe1 M3z6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;yeHNKSzVyPUKzNU46ODVizszN NVi5fIJiW0GQR1XS
CCRF-CEM MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jzWWlEPTB;MkSzMlc6PSEQvF2= Mn7XV2FPT0WU
SH-4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ2Nj6wPUDPxE1? MUTTRW5ITVJ?
LS-1034 NX\PWZhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjQVXh3UUN3ME2yOFYvOjZ4IN88US=> MYXTRW5ITVJ?
NCI-H2347 NUX5NYpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\YTWM2OD1{NEeuO|E{KM7:TR?= M1zDW3NCVkeHUh?=
RPMI-8866 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjxOnlKSzVyPUK0PU4zPyEQvF2= NI\aVI9USU6JRWK=
GAK NEDLOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJ3Mz6wNFIh|ryP MX;TRW5ITVJ?
NB6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnweoc2UUN3ME2yO|AvOSEQvF2= MkTvV2FPT0WU
COLO-680N M1vEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ5Mj61Nlch|ryP NWP5PZN5W0GQR1XS
RERF-LC-MS NXjvWFB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\YcY14UUN3ME2yO|YvODB5IN88US=> MnHjV2FPT0WU
TGBC11TKB NETmR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILzT4VKSzVyPUK3PE4yPzhizszN NIrXPG1USU6JRWK=
C8166 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID4[ZJKSzVyPUK3PE42ODZizszN NIriVm1USU6JRWK=
HDLM-2 NU\2WZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjXeGNKSzVyPUK5OE41ODlizszN M3zY[nNCVkeHUh?=
IGR-1 M3jRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13nR2lEPTB;Mkm1MlY2QSEQvF2= M1[zXXNCVkeHUh?=
FADU NGDZXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLHTWM2OD1{OUeuOVEh|ryP MWHTRW5ITVJ?
L-428 NHG4cIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjTbW5QUUN3ME2yPVcvPjF4IN88US=> NH\CTFlUSU6JRWK=
LU-65 NVfXSItTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni2TWM2OD1|MESuN|Ih|ryP NF\4WZRUSU6JRWK=
HEL NFrNNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNyOT65PFMh|ryP M4q2fXNCVkeHUh?=
NCI-H810 Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC1N5VKSzVyPUOxNE42PyEQvF2= Ml:wV2FPT0WU
C3A MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln6TWM2OD1|MUGuPFAzKM7:TR?= MoLnV2FPT0WU
NCI-H630 NFr5eHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfCTWM2OD1|M{KuNlk1KM7:TR?= Mmq1V2FPT0WU
KP-N-YN M2HZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN2MT6xNlMh|ryP NF2yVXJUSU6JRWK=
MOLT-13 Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml20TWM2OD1|NEKuN|I3KM7:TR?= MXvTRW5ITVJ?
NCI-H1993 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor0TWM2OD1|NEKuN|Y2KM7:TR?= NGXwZ2dUSU6JRWK=
BE-13 M2LPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnRV5NKSzVyPUO0OE4yPjdizszN M333cnNCVkeHUh?=
IST-SL1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTN2Nz60NFEh|ryP MV\TRW5ITVJ?
TE-9 M2\LdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\hOmlEPTB;M{[zMlU5QSEQvF2= NGXHSIRUSU6JRWK=
LU-135 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV25XJBkUUN3ME2zOlcvODN3IN88US=> NXm0S2t4W0GQR1XS
T84 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlyzTWM2OD1|N{SuO|EzKM7:TR?= MoTUV2FPT0WU
K-562 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr0TWM2OD1|OEOuN|Yh|ryP NXXocoVEW0GQR1XS
SBC-5 NXHUeIx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrTXVhKSzVyPUO4Ok46QDVizszN MXjTRW5ITVJ?
NB17 M{PMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rLWWlEPTB;M{myMlU6PiEQvF2= M4L3[HNCVkeHUh?=
NCI-H2052 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITYUIZKSzVyPUO5PE41PzJizszN Ml;JV2FPT0WU
HCC38 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzsSnFuUUN3ME20NFEvPTl|IN88US=> NFzHTZpUSU6JRWK=
NCI-H69 NVfjO2RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XYfWlEPTB;NESxMlA5OyEQvF2= MmHwV2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 MK-2206和这些细胞毒素药剂联用作用于NCI-H292移植瘤,MK-2206显示出非常有效的抗癌活性。卵巢癌A2780移植瘤中,按动物体重,每千克处理240mg MK-2206,则可抑制70%以上的Akt1/2在苏氨酸308位点和丝氨酸473位点的磷酸化,导致肿瘤生长抑制率达到60%。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[3]

+ 展开

Akt激酶实验:

通过得到的GSK 生物素肽段基质测定Akt激酶。使用含镧系金属螯合物偶联单抗的均相时间分辨荧光(HTRF)测定肽段磷酸化程度,这种单抗专门作用于与链霉亲和素——藻蓝素(SA-APC)载体相结合的磷酸化作用,SA-APC载体可以结合到肽段的部分生物素上。当镧系金属螯合物与藻蓝素相接触时,无辐射的能量从镧系金属螯合物传递给藻蓝素,然后藻蓝素发射波值为655纳米的光线。工作液:100X 蛋白酶抑制剂混合物(PIC):1mg/ml苯甲脒,0.5 mg/ml 抑肽素, 0.5 mg/ml亮抑肽酶, 0.5 mg/ml 抑肽酶。10X实验 buffer: 500 mM HEPES(pH 为7.5), 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-甘油磷酸。抑制 buffer:50 mM HEPES(pH为7.3), 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM 标记的单抗, 0.0067mg/ml SA-APC。ATP/MgCl2工作液: 1X 实验buffer, 1 mM DTT, 1X PIC, 5% 甘油, 激活的Akt。肽段工作液:1X实验buffer, 1 mM DTT, 1X PIC, 5% 甘油 2 TM GSK生物素肽段。工作液加到合适的孔中,然后加入总负荷为16的 ATP/MgCl2,反应开始。含MK-2206的实验组和对照组加入总负荷为10的肽段工作液。然后加入总负荷为13的酶液,混匀。反应进行50分钟,然后加入总负荷为60的均相时间分辨荧光抑制buffer停止反应。阻断的反应在室温下温育30分钟以上,然后使用仪器读数。
细胞实验:

[2]

+ 展开
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6,和NCI-H460细胞
  • Concentrations: 0, 0.3, 1,和3 μM
  • Incubation Time: 72或96小时
  • Method:

    MK-2206溶解在DMSO中,在实验使用前用培养基稀释。细胞按2~3×103密度接种在96孔板上,温育24小时。MK-2206 (分为0, 0.3, 1,和3 μmol四组)处理细胞,72或者96小时后,测定细胞增殖情况。


    (Only for Reference)
动物实验:

[2]

+ 展开
  • Animal Models: 携带SK-OV-3, NCI-H292, HCC70, PC-3,和NCI-H460模型的雄性CD1裸鼠
  • Formulation: 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
15% Captisol
17 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 480.39
化学式

C25H21N5O.2HCl

CAS号 1032350-13-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01802320 Active not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01783171 Completed Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 15 2013 Phase 1
NCT01776008 Terminated Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1
NCT01658943 Completed Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage IV Pancreatic Cancer National Cancer Institute (NCI) August 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • 回答:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • 问题 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • 回答:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

相关Akt产品

Tags: 购买MK-2206 2HCl | MK-2206 2HCl供应商 | 采购MK-2206 2HCl | MK-2206 2HCl价格 | MK-2206 2HCl生产 | 订购MK-2206 2HCl | MK-2206 2HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID